REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
REGENERON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$782.04−8.70 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
89.0%
92M of 103M shares
Institutional holders
1,332
122 new, 168 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 84 sales
Net sold $12.91M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8,629,707 | 8.10% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 7,660,810 | 7.37% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of REGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,113,506 | 8.85% | $5.68B | +165,771 | 0.08% |
| Vanguard Capital Management LLC | 6,629,759 | 6.44% | $4.13B | −25,154 | 0.09% |
| Dodge & Cox | 4,871,137 | 4.73% | $3.04B | +412,899 | 1.59% |
| State Street Corp | 4,834,688 | 4.70% | $3.01B | +170,210 | 0.09% |
| Invesco Ltd. | 3,940,665 | 3.83% | $2.46B | +35,556 | 0.19% |
| JPMorgan Chase & Co | 3,774,199 | 3.67% | $2.38B | −537,607 | 0.13% |
| Vanguard Portfolio Management LLC | 3,175,313 | 3.08% | $1.98B | +1,454,539 | 0.09% |
| Franklin Resources Inc | 2,771,839 | 2.69% | $1.73B | +49,768 | 0.37% |
| Geode Capital Management, LLC | 2,625,810 | 2.55% | $1.63B | +18,078 | 0.09% |
| Nuveen, LLC | 2,019,974 | 1.96% | $1.26B | −45,090 | 0.30% |
| Loomis Sayles & Co L P | 1,859,172 | 1.81% | $1.16B | −53,138 | 1.45% |
| Price T Rowe Associates Inc /Md/ | 1,529,709 | 1.49% | $953.84K | −647,818 | 0.10% |
| Morgan Stanley | 1,397,712 | 1.36% | $871.53M | +78,383 | 0.05% |
| Bank Of America Corp /De/ | 1,291,053 | 1.25% | $805.02M | +101,469 | 0.05% |
| Wellington Management Group Llp | 1,270,087 | 1.23% | $791.95M | −567,372 | 0.14% |
| Norges Bank | 1,172,808 | 1.14% | $731.29M | New | 0.07% |
| Goldman Sachs Group Inc | 1,163,191 | 1.13% | $725.30M | −137,367 | 0.06% |
| Aqr Capital Management LLC | 1,126,080 | 1.09% | $702.16M | −104,928 | 0.24% |
| Amundi | 1,013,540 | 0.98% | $631.98M | +3,742 | 0.15% |
| Northern Trust Corp | 916,467 | 0.89% | $571.45M | −25,474 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,332 | 92M | 89.0% | 122 / 485 | 538 / 168 | 9M | 8M |
| Q1 2026 | 1,399 | 91M | 87.9% | 137 / 575 | 464 / 102 | 16M | 8M |
| Q4 2025 | 1,386 | 92M | 89.3% | 272 / 501 | 457 / 107 | 13M | 12M |
| Q3 2025 | 1,244 | 91M | 88.6% | 173 / 488 | 418 / 112 | 12M | 10M |
| Q2 2025 | 1,202 | 90M | 87.2% | 134 / 443 | 476 / 207 | 10M | 13M |
| Q1 2025 | 1,290 | 93M | 90.6% | 141 / 527 | 452 / 148 | 7M | 7M |
| Q4 2024 | 1,317 | 94M | 91.0% | 169 / 479 | 494 / 215 | 9M | 17M |
| Q3 2024 | 1,391 | 101M | 98.5% | 142 / 541 | 464 / 70 | 13M | 6M |
| Q2 2024 | 1,334 | 103M | 99.7% | 125 / 547 | 430 / 84 | 5M | 5M |
| Q1 2024 | 1,310 | 104M | 100.0% | 149 / 483 | 449 / 96 | 8M | 3M |
| Q4 2023 | 1,273 | 100M | 97.1% | 186 / 441 | 443 / 68 | 13M | 4M |
| Q3 2023 | 1,178 | 91M | 88.6% | 111 / 400 | 447 / 88 | 4M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of REGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,270,896 | 3.18% | $2.04B | 0.09% | Jun 30, 2026 |
| Dodge & Cox Stock Fund | 3,121,304 | 3.03% | $1.95B | 1.64% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,588,231 | 2.51% | $1.61B | 0.10% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2,186,867 | 2.12% | $1.36B | 0.28% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,374,351 | 1.33% | $856.96M | 0.10% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,289,978 | 1.25% | $793.05M | 0.10% | May 31, 2026 |
| Putnam Large Cap Value Fund | 1,152,014 | 1.12% | $878.56M | 1.59% | Jul 31, 2026 |
| Vanguard Mid-Cap Index Fund | 1,116,182 | 1.08% | $695.98M | 0.31% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,072,221 | 1.04% | $817.71M | 2.14% | Jul 31, 2026 |
| Vanguard Value Index Fund | 981,751 | 0.95% | $612.16M | 0.24% | Jun 30, 2026 |
| JPMorgan Equity Premium Income ETF | 752,509 | 0.73% | $469.22M | 1.05% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 727,411 | 0.71% | $453.57M | 0.31% | Jun 30, 2026 |
| iShares Biotechnology ETF | 715,060 | 0.69% | $445.87M | 4.91% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 705,889 | 0.69% | $440.15M | 1.08% | Jun 30, 2026 |
| College Retirement Equities Fund - Growth Account | 586,888 | 0.57% | $365.95M | 0.85% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Leonard S. Schleifer | Bd. Co-Chair, President & CEO, Director | 2,442,116 | 2.37% | Jan 5, 2026 |
| George Yancopoulos | Bd. Co-Chair, President & CSO, Director | 1,168,695 | 1.14% | Jan 5, 2026 |
| Marion McCourt | EVP Commercial | 12,222 | 0.01% | Sep 3, 2026 |
| Joseph J. Larosa | EVP General Counsel and Secret | 54,614 | 0.05% | Aug 21, 2026 |
| Christopher R. Fenimore | EVP Finance CFO | 23,505 | 0.02% | Aug 20, 2026 |
| Jason Pitofsky | SVP Controller | 5,586 | 0.01% | Feb 11, 2026 |
| Plew Daniel P. Van | EVP & General Mgr, Industrial | 35,178 | 0.03% | Dec 11, 2025 |
| Andrew J. Murphy | EVP Research | 52,208 | 0.05% | Dec 11, 2025 |
| Neil Stahl | EVP Research and Development | 59,283 | 0.06% | Dec 18, 2024 |
| Kathryn Guarini | Director | 603 | 0.00% | Sep 3, 2026 |
| Huda Y. Zoghbi | Director | 1,703 | 0.00% | Aug 12, 2026 |
| Arthur F. Ryan | Director | 17,303 | 0.02% | Jul 7, 2026 |
| Bonnie L. Bassler | Director | 3,203 | 0.00% | Jan 8, 2026 |
| Joseph L. Goldstein | Director | 6,703 | 0.01% | Jan 6, 2026 |
| Christine A. Poon | Director | 5,219 | 0.01% | Jan 6, 2026 |
| Craig B. Thompson | Director | 775 | 0.00% | Jan 6, 2026 |
| N. Anthony Coles | Director | 1,714 | 0.00% | Jan 6, 2026 |
| David P. Schenkein | Director | 603 | 0.00% | Jan 6, 2026 |
| George L. Sing | Director | 33,157 | 0.03% | Jan 6, 2026 |
| Michael S. Brown | Director | 12,865 | 0.01% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marion McCourt EVP Commercial | Sep 3, 2026 | Sale(10b5-1 plan) | −1,131 | $857.39 | $969.71K | 12,003 |
| Kathryn Guarini Director | Sep 2, 2026 | Sale(10b5-1 plan) | −400 | $850.00 | $340.00K | 603 |
| Kathryn Guarini Director | Sep 2, 2026 | Option exercise | +400 | $719.37 | $287.75K | 1,003 |
| Marion McCourt EVP Commercial | Sep 2, 2026 | Sale(10b5-1 plan) | −1,215 | $850.00 | $1.03M | 13,134 |
| Joseph J. Larosa EVP General Counsel and Secret | Aug 19, 2026 | Option exercise | +12,282 | $381.92 | $4.69M | 45,392 |
| Joseph J. Larosa EVP General Counsel and Secret | Aug 19, 2026 | Tax withholding | −9,019 | $830.15 | $7.49M | 36,373 |
| Christopher R. Fenimore EVP Finance CFO | Aug 18, 2026 | Tax withholding | −4,599 | $813.47 | $3.74M | 19,984 |
| Christopher R. Fenimore EVP Finance CFO | Aug 18, 2026 | Option exercise | +6,283 | $381.92 | $2.40M | 24,583 |
| Huda Y. Zoghbi Director | Aug 10, 2026 | Sale(10b5-1 plan) | −800 | $800.00 | $640.00K | 1,703 |
| Huda Y. Zoghbi Director | Aug 10, 2026 | Option exercise | +800 | $376.69 | $301.35K | 2,503 |
| Kathryn Guarini Director | Aug 10, 2026 | Option exercise | +400 | $719.37 | $287.75K | 1,003 |
| Kathryn Guarini Director | Aug 10, 2026 | Sale(10b5-1 plan) | −400 | $800.00 | $320.00K | 603 |
| Arthur F. Ryan Director | Jul 2, 2026 | Sale(10b5-1 plan) | −200 | $650.15 | $130.03K | 17,303 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −15 | $702.46 | $10.54K | 17,583 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −5 | $701.76 | $3.51K | 17,598 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −24 | $703.46 | $16.88K | 17,559 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −15 | $704.28 | $10.56K | 17,544 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −14 | $705.56 | $9.88K | 17,530 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −7 | $706.74 | $4.95K | 17,523 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −6 | $709.45 | $4.26K | 17,513 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −4 | $707.40 | $2.83K | 17,519 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −2 | $714.13 | $1.43K | 17,503 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −1 | $712.09 | $712 | 17,505 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −5 | $711.49 | $3.56K | 17,506 |
| Arthur F. Ryan Director | May 1, 2026 | Sale(10b5-1 plan) | −2 | $710.87 | $1.42K | 17,511 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −8 | $774.58 | $6.20K | 17,683 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −1 | $771.32 | $771 | 17,702 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −3 | $772.76 | $2.32K | 17,699 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −8 | $773.59 | $6.19K | 17,691 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −14 | $775.58 | $10.86K | 17,669 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −40 | $779.71 | $31.19K | 17,603 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −4 | $778.24 | $3.11K | 17,643 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −9 | $777.42 | $7.00K | 17,647 |
| Arthur F. Ryan Director | Apr 1, 2026 | Sale(10b5-1 plan) | −13 | $776.62 | $10.10K | 17,656 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −9 | $784.48 | $7.06K | 17,763 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −20 | $789.28 | $15.79K | 17,703 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −3 | $780.69 | $2.34K | 17,786 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −5 | $779.69 | $3.90K | 17,789 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −2 | $778.30 | $1.56K | 17,794 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −7 | $777.46 | $5.44K | 17,796 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −2 | $782.62 | $1.57K | 17,782 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −10 | $783.62 | $7.84K | 17,772 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −2 | $781.21 | $1.56K | 17,784 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −11 | $785.48 | $8.64K | 17,752 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −7 | $786.61 | $5.51K | 17,745 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −2 | $787.34 | $1.57K | 17,743 |
| Arthur F. Ryan Director | Mar 2, 2026 | Sale(10b5-1 plan) | −20 | $788.96 | $15.78K | 17,723 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −50 | $775.50 | $38.78K | 3,242 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −53 | $778.47 | $41.26K | 3,189 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −208 | $779.55 | $162.15K | 2,981 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −331 | $780.45 | $258.33K | 2,650 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −209 | $781.28 | $163.29K | 2,441 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −298 | $782.10 | $233.07K | 2,143 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −220 | $783.29 | $172.32K | 1,923 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −49 | $774.68 | $37.96K | 3,292 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −56 | $785.61 | $43.99K | 1,707 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Option exercise | +1,638 | $376.69 | $617.02K | 3,341 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −160 | $784.45 | $125.51K | 1,763 |
| Huda Y. Zoghbi Director | Feb 19, 2026 | Sale(10b5-1 plan) | −4 | $790.00 | $3.16K | 1,703 |
| Arthur F. Ryan Director | Feb 9, 2026 | Sale(10b5-1 plan) | −10 | $776.59 | $7.77K | 17,892 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Andrew J. Murphy Officer | Oct 14, 2026 | 4,147 | $3.20M | Oct 14, 2026 | Exercise of Stock Options |
| Marion McCourt Officer | Sep 3, 2026 | 1,131 | $969.27K | Sep 3, 2026 | RSA Vesting |
| Kathryn Guarini Director | Sep 2, 2026 | 400 | $340.00K | Sep 2, 2026 | Exercise of stock option |
| Marion McCourt Officer | Sep 2, 2026 | 1,215 | $1.03M | Sep 2, 2026 | RSA Vesting |
| Kathryn Guarini Board member | Aug 10, 2026 | 400 | $320.00K | Aug 10, 2026 | Exercise of stock option |
| Huda Y. Zoghbi Director | Aug 10, 2026 | 800 | $640.00K | Aug 10, 2026 | Exercise of stock options |
| F. Ryan Arthur Director | Jul 2, 2026 | 400 | $249.89K | Jul 2, 2026 | Compensation |
| Huda Y. Zoghbi Director | Feb 19, 2026 | 1,638 | $1.29M | Feb 19, 2026 | Exercise of stock options |
| Jason Pitofsky Officer | Feb 9, 2026 | 2,036 | $1.59M | Feb 9, 2026 | Exercise of Stock Options |
| F. Ryan Arthur Director | Feb 9, 2026 | 400 | $314.20K | Feb 9, 2026 | Compensation |
| Bonnie L. Bassler Director | Jan 7, 2026 | 1,500 | $1.20M | Jan 7, 2026 | OPTION EXERCISE |
| Bonnie L. Bassler Director | Nov 20, 2025 | 760 | $570.00K | Nov 20, 2025 | OPTION EXERCISE |
| Pitofsky Jason Officer | Nov 7, 2025 | 431 | $280.58K | Nov 7, 2025 | Restricted Stock Award |
| Poon Christine Director | Oct 29, 2025 | 6,500 | $4.24M | Oct 29, 2025 | Acquired as compensation -- Stock Options |
| E. McCourt Marion Officer | Nov 1, 2024 | 1,000 | $844.61K | Nov 1, 2024 | Stock Option Exercise |